$2.41
3.21% yesterday
Nasdaq, May 02, 10:00 pm CET
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

AbCellera Biologics Inc Stock price

$2.41
+0.19 8.56% 1M
-0.48 16.61% 6M
-0.52 17.75% YTD
-1.44 37.40% 1Y
-5.66 70.14% 3Y
-17.59 87.95% 5Y
-17.59 87.95% 10Y
Nasdaq, Closing price Fri, May 02 2025
-0.08 3.21%
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

Key metrics

Market capitalization $718.15m
Enterprise Value $130.80m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.54
P/S ratio (TTM) P/S ratio 24.91
P/B ratio (TTM) P/B ratio 0.67
Revenue growth (TTM) Revenue growth -24.17%
Revenue (TTM) Revenue $28.83m
EBIT (operating result TTM) EBIT $-314.77m
Free Cash Flow (TTM) Free Cash Flow $-183.14m
Cash position $652.71m
EPS (TTM) EPS $-0.55
P/E forward negative
P/S forward 26.79
EV/Sales forward 4.88
Short interest 10.33%
Show more

Is AbCellera Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

AbCellera Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a AbCellera Biologics Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a AbCellera Biologics Inc forecast:

Buy
88%
Hold
13%

Financial data from AbCellera Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
29 29
24% 24%
100%
- Direct Costs 97 97
-
336%
-68 -68
-
-236%
- Selling and Administrative Expenses - -
- Research and Development Expense 167 167
5% 5%
580%
-218 -218
6% 6%
-755%
- Depreciation and Amortization 97 97
214% 214%
336%
EBIT (Operating Income) EBIT -315 -315
33% 33%
-1,092%
Net Profit -163 -163
11% 11%
-565%

In millions USD.

Don't miss a Thing! We will send you all news about AbCellera Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbCellera Biologics Inc Stock News

Neutral
Business Wire
4 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.
Neutral
Business Wire
25 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in May and June.
Neutral
Business Wire
30 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025.
More AbCellera Biologics Inc News

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Carl Hansen
Employees 596
Founded 2012
Website www.abcellera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today